Regular Article
Effects of a β3-Adrenergic Agonist on Glucose Uptake and Leptin Expression and Secretion in Cultured Adipocytes from Lean and Overweight (Cafeteria) Rats

https://doi.org/10.1006/bbrc.2002.6577Get rights and content

Abstract

The increase in body and white adipose tissue weights induced by a high-fat diet were prevented by treatment with the β3-adrenergic agonist Trecadrine. Plasma insulin levels were slightly elevated in overweight rats, while a decrease was observed in Trecadrine-treated groups. Insulin-dependent glucose uptake was impaired in adipocytes of the overweight rats in relation to lean animals. The β3-adrenergic agonist induced an increase in insulin-stimulated glucose uptake by adipocytes as compared to the nontreated animals. In fact, Trecadrine treatment was able to restore to control values the impairment in insulin-mediated glucose uptake induced by the cafeteria diet, suggesting that Trecadrine prevents the development of insulin resistance in overweight animals. Basal leptin secretion was increased in adipocytes of the overweight rats in relation to lean animals. Trecadrine treatment induced a decrease in basal leptin secretion compared to the untreated animals. Insulin-stimulated leptin secretion reached similar levels in adipocytes of the overweight rats as in lean animals. There was a trend for insulin-induced leptin secretion to be lower at 24 h in Trecadrine-treated rats, but it did not reach statistical significance. In conclusion, adipocytes of diet-induced overweight animals have a higher basal leptin secretion, which is reduced by treatment with Trecadrine. However, neither the cafeteria diet nor the Trecadrine treatment significantly alters the ability of adipocytes to increase leptin secretion in response to insulin.

References (33)

  • Y. Matsuzawa et al.

    Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances

    Ann. NY Acad. Sci.

    (1999)
  • R.N. Bergman et al.

    Central role of the adipocyte in the insulin resistance

    J. Basic Clin. Physiol. Pharmacol.

    (1998)
  • C. Weyer et al.

    Development of beta3-adrenoceptor agonists for the treatment of obesity and diabetes-an update

    Diabetes & Metabolism

    (1999)
  • M. Barrionuevo et al.

    Potential anti-diabetic applications of a new molecule with affinity for β3-adrenoceptors

    Life Sci.

    (1996)
  • B. Berraondo et al.

    Effects on energy utilization of a β3-adrenergic agonist in rats fed on a cafeteria diet

    Eating Weight Disord.

    (1997)
  • B. Berraondo et al.

    Up-regulation of muscle UCP2 gene expression by a new beta-3 adrenoceptor agonist, trecadrine, in obese (cafeteria) rodents, but down-regulation in lean animals

    Int. J. Obes. Relat. Metab. Disord.

    (2000)
  • Cited by (0)

    1

    To whom correspondence and reprint requests should be addressed Fax: 948-425649. E-mail: [email protected].

    View full text